Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.
Real-world European data continues to track whether popular diabetes drugs raise thyroid cancer risk, refining safety understanding for millions of users.
This pharmacovigilance analysis of the European pharmacovigilance database investigated thyroid cancer-related adverse event signals for GLP-1 receptor agonists, contributing to the ongoing real-world safety surveillance of this widely used drug class. The study adds European population data to the safety characterization of GLP-1 RA thyroid risk, which remains clinically relevant given widespread prescribing.
What the study was
- Study design
- Pharmacovigilance disproportionality analysis (European pharmacovigilance database)
- Population
- GLP-1 RA users reporting adverse events to European pharmacovigilance database
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Pharmacol Rep
Why it surfaced
Pharmacovigilance study addressing ongoing thyroid cancer safety concern with GLP-1 RAs; relevant given massive patient exposure. Abstract did not provide specific ROR values; medium confidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.